<DOC>
	<DOC>NCT02277106</DOC>
	<brief_summary>Stage 1 is a double-blind, proof-of-concept study designed to evaluate the safety, tolerability, PK, and efficacy of SAGE-547 Injection in male and female patients with essential tremor in the upper limb. Stage 2 is an open-label arm designed to evaluate the safety, tolerability, PK, and effeciveness of SAGE-547 Injection at a higher dose than in Stage 1. Subjects who completed Stage 1 will be invited to participate in Stage 2.</brief_summary>
	<brief_title>Evaluate SAGE-547 in Patients With Essential Tremor</brief_title>
	<detailed_description />
	<mesh_term>Tremor</mesh_term>
	<mesh_term>Essential Tremor</mesh_term>
	<criteria>Males and females, 3575 years old with a diagnosis of essential tremor with symptoms clearly present in at least 1 upper limb; patient has had tremor present for at least 2 years prior to Screening Off medication, or on a stable dose of medication for their tremor for at least 28 days prior to Screening Recent history or active clinically significant manifestations of metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, musculoskeletal, dermatological, urogenital, eyes, ears, nose, or throat, psychiatric, or neurological (other than essential tremor) disorders Medical history of seizures</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>